ISRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intuitive Surgical Inc (ISRG) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive congress trading sentiment, and analyst optimism outweigh the minor technical and competitive concerns. Despite a slightly negative pre-market price change, the long-term growth prospects and secular growth story make this a compelling investment opportunity.
The MACD is above 0 and positively contracting, indicating a bullish trend. RSI is neutral at 45.543, and moving averages are converging, showing no strong directional bias. The stock is trading near its pivot level of 499.386, with support at 489.672 and resistance at 509.1.
Congress members have made 4 purchase transactions in the last 90 days, indicating strong confidence in the stock.
Financial performance in Q4 2025 showed robust growth, with revenue up 18.76% YoY and net income up 15.91% YoY.
Analysts have provided optimistic ratings and price targets, with several firms highlighting the company's secular growth story and strong procedure growth outlook.
Recent acquisitions in Europe enhance the company's operational footprint.
Insiders are selling, with a 144.61% increase in selling activity over the last month.
Increased competition from Medtronic's Hugo surgical robot, which recently received FDA approval.
The stock's high valuation (P/E ratio of
compared to competitors like Medtronic (P/E ratio of
could deter some investors.
In Q4 2025, revenue increased by 18.76% YoY to $2.87 billion, net income rose by 15.91% YoY to $794.8 million, and EPS grew by 17.55% YoY to $2.21. However, gross margin dropped slightly to 66.44%, down 2.35% YoY.
Analysts are generally positive on ISRG, with recent upgrades and raised price targets. Notable ratings include Barclays raising the price target to $712, Goldman Sachs to $714, and Bernstein to $750. Analysts highlight the company's strong growth outlook, procedure volume growth, and robust financial performance.
